Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028248 · ClinicalTrials.gov registry record · Phase 1
Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
A Phase 1 study, sponsored by California Retina Consultants.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01028248 is a Phase 1 study that has completed, run by California Retina Consultants. The registered enrollment target is 20 participants.
The verdict
NCT01028248, a Phase 1 study, has completed, sponsored by California Retina Consultants.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ranibizumab (Lucentis) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
Interventions
- DRUG Ranibizumab (Lucentis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028248
The ClinicalTrials.gov registry entry for NCT01028248 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Retina Consultants, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab (Lucentis) is the first listed.
NCT01028248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028248 about?
NCT01028248 is a clinical study titled "Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion". The purpose of this study is to determine whether ranibizumab (Lucentis) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
What is the current status of trial NCT01028248?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01028248?
The interventions under investigation include: Ranibizumab (Lucentis) (DRUG).
Who is sponsoring clinical trial NCT01028248?
This trial is sponsored by California Retina Consultants, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.